Immuneering (IMRX) Cash from Operations (2020 - 2024)
Historic Cash from Operations for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$14.5 million.
- Immuneering's Cash from Operations fell 2322.94% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.0 million, marking a year-over-year decrease of 1231.59%. This contributed to the annual value of -$55.0 million for FY2024, which is 1231.59% down from last year.
- Immuneering's Cash from Operations amounted to -$14.5 million in Q4 2024, which was down 2322.94% from -$13.5 million recorded in Q3 2024.
- In the past 5 years, Immuneering's Cash from Operations ranged from a high of -$3.5 million in Q3 2020 and a low of -$15.5 million during Q1 2024
- Moreover, its 5-year median value for Cash from Operations was -$11.1 million (2023), whereas its average is -$10.4 million.
- Per our database at Business Quant, Immuneering's Cash from Operations plummeted by 15916.69% in 2021 and then fell by 22.63% in 2023.
- Over the past 5 years, Immuneering's Cash from Operations (Quarter) stood at -$5.5 million in 2020, then tumbled by 69.43% to -$9.2 million in 2021, then fell by 27.16% to -$11.7 million in 2022, then decreased by 0.23% to -$11.8 million in 2023, then fell by 23.23% to -$14.5 million in 2024.
- Its Cash from Operations stands at -$14.5 million for Q4 2024, versus -$13.5 million for Q3 2024 and -$11.5 million for Q2 2024.